Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kalaris Therapeutics, Inc.KLRS · Entity 6805 | Chief Medical Officer | March 19, 2026 | March 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kalaris Therapeutics, Inc.
Report date March 19, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.81 · Expires 2036-03-18 | Direct | 135,000 |
Reported balance
After 2026-03-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-19 · Grant · Acquired 135,000 · Balance 135,000 F1: The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
APPLIED GENETIC TECHNOLOGIES CORP
Report date July 29, 2019 · Filed July 31, 2019
Section 16 reporting ended · disclosed 2019-07-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.91 · Expires 2029-07-29 | Direct | 100,000 |
Reported balance
After 2019-07-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-29 · Grant · Acquired 100,000 · Balance 100,000 F1: Option becomes exercisable based on the achievement of certain performance milestones. For each milestone met, the option vests as to 16,666.6667 shares of the Company's common stock in accordance with the following schedule: 25% of the underlying shares for such milestone vest on achievement of such milestone, and thereafter the remaining underlying shares for such milestone vest in equal monthly installments over three years, resulting in the option being exercisable for 100% of the underlying shares for such milestone on the third anniversary of the achievement of the applicable milestone. |
Filing footnotes · ownership attribution and instrument terms
F1: Option becomes exercisable based on the achievement of certain performance milestones. For each milestone met, the option vests as to 16,666.6667 shares of the Company's common stock in accordance with the following schedule: 25% of the underlying shares for such milestone vest on achievement of such milestone, and thereafter the remaining underlying shares for such milestone vest in equal monthly installments over three years, resulting in the option being exercisable for 100% of the underlying shares for such milestone on the third anniversary of the achievement of the applicable milestone.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2026 Filed Mar 20, 2026 20:05 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001193125-26-117616 · ownership.xml · derivative · entry 1 Feinsod Matthew · CIK 0001716950 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2036-03-18 F1 · derivative.exercise_date: The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:52 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 101,000 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0000950170-25-053338 · ownership.xml · derivative · entry 2 Feinsod Matthew · CIK 0001716950 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,000 Underlying: Common Stock · 101,000 shares Expires 2035-04-09 F2 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:52 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 70,551 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0000950170-25-053338 · ownership.xml · derivative · entry 1 Feinsod Matthew · CIK 0001716950 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,551 Underlying: Common Stock · 70,551 shares Expires 2035-04-09 F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on December 31, 2025, and the remainder vesting in equal monthly installments thereafter, subject to continuous service. Read SEC document |
| March 18, 2025 Filed Mar 18, 2025 21:43 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantStock Option (right to buy) · Derivative | 28,224 | Not disclosed Strike: $0.85 | Not disclosed |
DisclosureSEC source: 0000950170-25-041494 · ownership.xml · derivative · entry 2 Feinsod Matthew · CIK 0001716950 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,224 Underlying: Common Stock · 28,224 shares Expires 2034-07-22 F3 · date: Stock option assumed in connection with the closing of the Merger, in exchange for an outstanding option to purchase shares of KTx pursuant to the terms and conditions of the Merger Agreement. F2 · price: Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer (the "Exchange Ratio") and each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger. F4 · derivative.exercise_date: This option vests over four years beginning on the vesting commencement date of June 17, 2024, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter. Read SEC document |
| March 18, 2025 Filed Mar 18, 2025 21:43 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantCommon Stock | 4,030 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-041494 · ownership.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,030 F1 · date: Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the "Merger Agreement"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation ("KTx"), in exchange for outstanding shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the "Merger"). F2 · price: Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer (the "Exchange Ratio") and each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:28 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001273636-19-000022 · edgar.xml · derivative · entry 1 Feinsod Matthew · CIK 0001716950 · Exec. VP, Global Strat. & Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-07-29 F1 · derivative.exercise_date: Option becomes exercisable based on the achievement of certain performance milestones. For each milestone met, the option vests as to 16,666.6667 shares of the Company's common stock in accordance with the following schedule: 25% of the underlying shares for such milestone vest on achievement of such milestone, and thereafter the remaining underlying shares for such milestone vest in equal monthly installments over three years, resulting in the option being exercisable for 100% of the underlying shares for such milestone on the third anniversary of the achievement of the applicable milestone. Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 16:45 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 592 | $3.75 | $2,220.00 |
DisclosureSEC source: 0001273636-19-000019 · edgar.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,052 Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 16:45 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001273636-19-000019 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,644 F1 · shares: The common stock vested immediately upon grant. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 19:21 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 685 | $3.77 | $2,582.45 |
DisclosureSEC source: 0001273636-19-000015 · edgar.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,644 Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 19:21 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001273636-19-000015 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,329 F1 · shares: The common stock vested immediately upon grant. Read SEC document |
| June 11, 2019 Filed Jun 20, 2019 16:39 UTC Amendment | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 685 | $3.70 | $2,534.50 |
DisclosureSEC source: 0001273636-19-000017 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,644 F1 · price: This Form 4/A is being filed to correct an administrative error in the reported price of the securities forfeited for tax witholding purposes. Read SEC document |
| May 13, 2019 Filed May 15, 2019 16:21 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 685 | $4.20 | $2,877.00 |
DisclosureSEC source: 0001273636-19-000010 · edgar.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,329 Read SEC document |
| May 13, 2019 Filed May 15, 2019 16:21 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001273636-19-000010 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,014 F1 · shares: The common stock vested immediately upon grant. Read SEC document |
| May 13, 2019 Filed May 20, 2019 16:02 UTC Amendment | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 685 | $4.06 | $2,781.10 |
DisclosureSEC source: 0001273636-19-000011 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,329 F1 · price: This Form 4/A is being filed to correct an administrative error in the reported price of the securities forfeited for tax witholding purposes. Read SEC document |
| April 11, 2019 Filed Apr 15, 2019 17:42 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 606 | $4.61 | $2,793.66 |
DisclosureSEC source: 0001273636-19-000009 · edgar.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,014 Read SEC document |
| April 11, 2019 Filed Apr 15, 2019 17:42 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001273636-19-000009 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,620 F1 · shares: The common stock vested immediately upon grant. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 17:16 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 667 | $3.97 | $2,647.99 |
DisclosureSEC source: 0001273636-19-000008 · edgar.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,620 Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 17:16 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001273636-19-000008 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,287 F1 · shares: The common stock vested immediately upon grant. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 18:30 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 791 | $3.29 | $2,602.39 |
DisclosureSEC source: 0001273636-19-000006 · edgar.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,287 Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 18:30 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001273636-19-000006 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,078 F1 · shares: The common stock vested immediately upon grant. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 19:58 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 713 | $3.20 | $2,281.60 |
DisclosureSEC source: 0001273636-19-000003 · edgar.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,078 Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 19:58 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001273636-19-000003 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,791 F1 · shares: The common stock vested immediately upon grant. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 21:23 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 611 | $6.11 | $3,733.21 |
DisclosureSEC source: 0001273636-18-000077 · edgar.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,791 Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 21:23 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001273636-18-000077 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,402 F1 · shares: The common stock vested immediately upon grant. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 16:43 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 685 | $7.05 | $4,829.25 |
DisclosureSEC source: 0001273636-18-000060 · edgar.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,402 Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 16:43 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001273636-18-000060 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,087 F1 · shares: The common stock vested immediately upon grant. Read SEC document |
| October 11, 2018 Filed Oct 15, 2018 19:01 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 612 | $6.46 | $3,953.52 |
DisclosureSEC source: 0001273636-18-000058 · edgar.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,087 Read SEC document |
| October 11, 2018 Filed Oct 15, 2018 19:01 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001273636-18-000058 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,699 F1 · shares: The common stock vested immediately upon grant. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 17:04 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 685 | $3.93 | $2,688.63 |
DisclosureSEC source: 0001273636-18-000051 · edgar.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,699 Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 17:04 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001273636-18-000051 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,384 F1 · shares: The common stock vested immediately upon grant. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 19:07 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 592 | $4.00 | $2,368.00 |
DisclosureSEC source: 0001273636-18-000049 · edgar.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,384 Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 19:07 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001273636-18-000049 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,976 F1 · shares: The common stock vested immediately upon grant. Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 17:57 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 685 | $4.15 | $2,842.75 |
DisclosureSEC source: 0001273636-18-000009 · edgar.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,976 Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 17:57 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001273636-18-000009 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,661 F1 · shares: The common stock vested immediately upon grant. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 19:33 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 606 | $4.55 | $2,757.30 |
DisclosureSEC source: 0001716950-18-000019 · edgar.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,661 Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 19:33 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001716950-18-000019 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,267 F1 · shares: The common stock vested immediately upon grant. Read SEC document |
| May 16, 2018 Filed May 18, 2018 18:17 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 3,425 | $5.60 | $19,180.00 |
DisclosureSEC source: 0001716950-18-000017 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,267 F1 · shares: Shares forfeited in connection with tax withholding as a result of vesting of restricted stock awarded on March 28, 2018. Read SEC document |
| May 11, 2018 Filed May 15, 2018 16:34 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 685 | $4.90 | $3,356.50 |
DisclosureSEC source: 0001716950-18-000015 · edgar.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,692 Read SEC document |
| May 11, 2018 Filed May 15, 2018 16:34 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001716950-18-000015 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,377 F1 · shares: The common stock vested immediately upon grant. Read SEC document |
| April 11, 2018 Filed Apr 13, 2018 16:20 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 685 | $4.00 | $2,740.00 |
DisclosureSEC source: 0001716950-18-000013 · edgar.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,377 Read SEC document |
| April 11, 2018 Filed Apr 13, 2018 16:20 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001716950-18-000013 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,062 F1 · shares: The common stock vested immediately upon grant. Read SEC document |
| March 28, 2018 Filed Mar 30, 2018 18:06 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001716950-18-000005 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,126 F1 · shares: The common stock shall vest on May 16, 2018, subject to Dr. Feinsod's continued employment. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 19:49 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 667 | $4.30 | $2,868.10 |
DisclosureSEC source: 0001716950-18-000003 · edgar.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,126 Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 19:49 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001716950-18-000003 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,793 F1 · shares: The common stock vested immediately upon grant. Read SEC document |
| February 11, 2018 Filed Feb 13, 2018 19:06 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001716950-18-000001 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,793 F1 · shares: The common stock vested immediately upon grant. Read SEC document |
| February 09, 2018 Filed Apr 6, 2018 20:45 UTC Amendment | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 733 | $3.95 | $2,895.35 |
DisclosureSEC source: 0001716950-18-000012 · edgar.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,729 F4 · shares: This Form 4/A amends the February Form 4 to report the number of shares withheld in connection with the reporting person's tax obligation with respect to the fully vested stock award. F4 · balance_after: This Form 4/A amends the February Form 4 to report the number of shares withheld in connection with the reporting person's tax obligation with respect to the fully vested stock award. Read SEC document |
| February 09, 2018 Filed Apr 6, 2018 20:45 UTC Amendment | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001716950-18-000012 · edgar.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,462 F1 · date: This Form 4/A amends the Form 4 previously filed on February 13, 2018 (the "February Form 4") in order to correct the transaction date from February 11, 2018 to February 9, 2018. F2 · shares: The common stock vested immediately upon grant. F3 · balance_after: Such number has been updated to reflect a Form 4 and a Form 4/A, each filed on the date hereof. The Form 4 reported the number of shares withheld in connection with the reporting person's tax obligation as a result of the vesting of a restricted stock award on December 11, 2017. The Form 4/A amended a Form 4 filed on January 16, 2018 to correct the number of shares withheld in connection with the reporting person's tax obligation as a result of a fully vested stock award. Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 20:29 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 855 | $4.30 | $3,676.50 |
DisclosureSEC source: 0000899243-18-001111 · doc4.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,793 Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 20:29 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-001111 · doc4.xml · nonDerivative · entry 1 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,648 F1 · shares: The common stock vested immediately upon grant. Read SEC document |
| January 11, 2018 Filed Apr 6, 2018 20:26 UTC Amendment | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 791 | $4.30 | $3,401.30 |
DisclosureSEC source: 0001716950-18-000010 · edgar.xml · nonDerivative · entry 2 Feinsod Matthew · CIK 0001716950 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,462 F3 · shares: This Form 4/A amends the Form 4 previously filed on January 16, 2018 to correct the number of shares withheld in connection with the reporting person's tax obligation as a result of the fully vested stock award. F3 · balance_after: This Form 4/A amends the Form 4 previously filed on January 16, 2018 to correct the number of shares withheld in connection with the reporting person's tax obligation as a result of the fully vested stock award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.